Prepared by Yujie Cheng · August 2026
Scope: Prescribing-only clinic (consultation model, no on-site dispensing)
Patient population: Adults aged 18+ only
Jurisdiction: Victoria, Australia
Working draft. All sources require final verification against current legislation. This document is not legal or regulatory advice.
1. Compliance matrix
A. Federal - TGA
| Requirement | Applies? | Key condition | Source |
|---|---|---|---|
| Authorised Prescriber (AP) approval | Yes - when prescribing to a class of patients | Product on Established History of Use list: no HREC needed. Otherwise, HREC approval or specialist-college endorsement is required. | TGA AP pathway guidance |
| Special Access Scheme B (SAS-B) | Yes - when prescribing per individual patient | Clinical justification per patient is required. Cost-based or personal-preference justifications are expressly unacceptable. | TGA SAS-B guidance |
| Online system registration | Source conflict exists | Treat online submission as the operational default. SAS material says submissions "must be lodged" online; AP guidance calls online filing the "preferred method"; an approved-forms instrument preserves a paper AP form available on request. | TGA SAS online system; AP online system; Therapeutic Goods (AP Scheme - Application Form) Approval (No. 2) 2024 |
| Prescription-medicine advertising compliance | Yes - Day 1 requirement | Review the business name, website, paid search, social media, booking funnel, and service descriptions. June 2026 guidance directly addresses services that prescribe or supply medicinal cannabis. TGA initiated Federal Court proceedings in August 2026 over alleged unlawful advertising. | TGA prescription-medicine advertising guidance (June 2026) |
B. State - Victoria
| Requirement | Applies? | Key condition | Source |
|---|---|---|---|
| Clinic operating licence | No - a prescribing-only clinic does not require separate health-service-establishment registration | Registration applies to private hospitals, day procedure centres, and mobile health services only. | Victorian Department of Health |
| Schedule 8 permit | Conditional | Required only for drug-dependent patients; not required for non-drug-dependent patients. | Victorian Department of Health - medicinal cannabis for health professionals |
| SafeScript check | Yes - every prescription | Prescriber must check SafeScript before each Schedule 8 medicinal-cannabis prescription, regardless of patient status. | Victorian Department of Health - SafeScript |
| Stock possession licence | Only if the clinic holds or supplies product on-site | If not exempt under a Commonwealth ODC licence, a separate Victorian licence is required under the Drugs, Poisons and Controlled Substances Act 1981. | Victorian Department of Health - licences and permits |
C. AHPRA / Medical Board
| Requirement | Applies? | Key condition | Source |
|---|---|---|---|
| Practitioner registration | General or Specialist registration required | Non-practising registration holders cannot prescribe. | AHPRA - types of medical registration |
| Specialist accreditation | Not required (adults 18+) | "Medical practitioners do not need to gain accreditation, nor be specialists in a particular field." | Victorian Department of Health FAQ |
| Medicinal-cannabis prescribing governance | Yes - critical | Full patient assessment; identified therapeutic need; not first-line treatment; management plan; continuity of care; records; exit strategy. "Patient demand is not an indicator of clinical need." AHPRA may investigate abnormally high prescribing volumes without a complaint. | Medical Board medicinal-cannabis prescribing guidance (2025) |
| Asynchronous prescribing constraint | Risk flag | Real-time video or telephone consultation is acceptable. Prescribing through questionnaires, email, text, or asynchronous chat without direct consultation is described as "not good practice" and is not supported by the Board. | Medical Board telehealth consultations |
| Conflict of interest | Risk flag | Single-product or single-class businesses and vertically integrated prescribing-supply arrangements are flagged by regulators as risk factors. | Medical Board guidance; TGA 2025 consultation |
2. Pathway sequence
Step 1 - Practitioner setup
- Confirm active AHPRA General or Specialist registration.
- Register on the TGA SAS & AP Online System.
- Estimated time: 1-3 days.
Step 2 - Advertising and branding compliance review
- Review the business name, website, and all marketing materials against TGA prescription-medicine advertising guidance.
- This step is non-negotiable before public launch.
- Estimated time varies; legal review is recommended.
Step 3 - Choose access pathway
- AP route (class of patients)
- Check if the product is on the Established History of Use list.
- If yes, submit the AP application; no HREC is needed.
- If no, obtain HREC approval or college endorsement first. Timeline: weeks to months.
- SAS-B route (individual patients)
- Submit a per-patient application with clinical justification.
Step 4 - TGA approval
- Medicinal cannabis applications: 2-5 business days after all required information is submitted.
- AP approval validity: up to five years; reports every six months.
- SAS-B validity is specified in the approval letter and is commonly granted for up to 24 months at delegate discretion.
- Since November 2021, substitution within the same approved category may not require a new TGA application. Moving outside the approved category does.
Step 5 - Victoria state compliance
- Register with SafeScript.
- Assess patient drug-dependency status.
- Non-dependent: no state permit needed.
- Dependent: apply for a Schedule 8 permit through SafeScript.
- Confirm that the clinic model does not require health-service-establishment registration.
Step 6 - Clinical governance setup
- Establish a full patient-assessment protocol.
- Document therapeutic need and treatment alternatives considered.
- Build management-plan and exit-strategy templates.
- Set up continuity-of-care and referral pathways.
- Declare and manage conflicts of interest, especially prescribing-supply arrangements.
- Establish medical-record and monitoring protocols.
3. Risk flags
| Risk | Detail | Potential impact |
|---|---|---|
| Advertising non-compliance | TGA is actively enforcing prescription-medicine advertising rules against medicinal-cannabis businesses. Business names, digital marketing, and booking funnels are in scope. | Federal Court proceedings are possible; a business-name change, website redesign, and marketing overhaul may be required before launch. |
| Asynchronous prescribing | Real-time telehealth is viable. Questionnaire-led or chat-only models without a live consultation are not supported by the Medical Board. | A virtual-first model works if built on real-time consultations; an async-only model creates regulatory liability. |
| Clinical-governance deficiency | AHPRA may investigate high-volume prescribers without a complaint. Short consultations, absent assessments, and demand-driven prescribing are explicit red flags. | Practitioner registration at risk; reputational damage to the clinic. |
| Conflict of interest | Vertically integrated prescribing and supply models, and single-product or single-class businesses, are specifically flagged by TGA and AHPRA. | Business-model design must address conflict management from Day 1. |
| Product-category boundary | Category-based approvals permit substitution only within the approved cannabinoid category, dosage form, and indication; substitution outside those boundaries requires a new TGA application. | Supply disruption may create an operational-continuity risk if a substitute crosses categories; risk is manageable within category. |
| Drug-dependent patient misclassification | Classifying a drug-dependent patient as non-dependent bypasses the Schedule 8 permit requirement. | Prescriber liability and enforcement action. |
4. Regulatory horizon scan (2025-2026)
| Date | Event | Status | Potential impact |
|---|---|---|---|
| Aug-Oct 2025 | TGA consultation: safety and regulatory-framework review | Feedback updated 21 Apr 2026; 786 submissions. Stakeholders broadly agreed the access framework was not fit for purpose or proportionate to potential safety and quality risks. | Signals reform direction; no new rules yet enacted. |
| 28 Jul 2026 | Medicinal Cannabis Expert Working Group - Meeting 8 (published 25 Aug 2026) | TGA outlined a staged reform program, including possible updates to TGO 93. Members discussed risks for palliative-care patients and vertically integrated telehealth models. | Any substantial TGO 93 amendments remain subject to consultation. |
| May 2026 | TGA guidance: compounded medicines, including medicinal cannabis | Published. | Additional restrictions for compounded cannabis products. |
| Jun 2026 | TGA guidance: prescription-medicine advertising | Published. | Active enforcement is underway and directly affects the marketing of medicinal-cannabis prescribing services. |
| Jun-Jul 2026 | Consultation: remaking the Narcotic Drugs Regulation 2016 | Closed in July 2026. | May affect cultivation and manufacturing licences, with downstream impacts on product supply. |
Assessment: No replacement prescribing framework has commenced, but reform has progressed beyond consultation stage. TGA is developing a staged reform program. Any clinic established now should build compliance review into its operating model at minimum six-month intervals. Advertising enforcement is not future; it is current.
5. Key insight
The formal licensing barrier for a prescribing-only Victorian clinic is relatively limited:
- No clinic-specific licence required.
- No specialist accreditation required for adults aged 18+.
- No state permit required for non-drug-dependent patients.
- TGA medicinal cannabis approval timeline: 2-5 business days, faster than the standard 15-day AP pathway.
- Category-based approvals reduce product-substitution friction.
The material regulatory risk sits in the clinical and commercial operating model, not in clinic establishment.
The question in 2026 is not "Can I legally establish this clinic?" but "Can I operate a high-volume, digitally acquired, virtual-first medicinal cannabis prescribing business without the business model itself distorting clinical decision-making or creating unlawful advertising?"
This is where regulators are focused: consultation quality, conflict of interest, advertising compliance, prescribing volumes, and single-purpose business models. A clinic that solves the licensing pathway but ignores operating-model governance has solved the wrong problem.
Sources
- Therapeutic Goods Administration
- Victorian Department of Health
- Australian Health Practitioner Regulation Agency
- Medical Board of Australia
- Office of Drug Control
Legislation references: Drugs, Poisons and Controlled Substances Act 1981 (Vic), Narcotic Drugs Act 1967 (Cth), and Therapeutic Goods (AP Scheme - Application Form) Approval (No. 2) 2024.
All dates and sources were verified against primary government pages as of August 2026.
Posted by Yujie Cheng on August 27, 2026.